Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 3Carcinoma, Renal Cell 2Uveal Melanoma 1Urologic Neoplasms 1Skin Neoplasms 1Neoplasms 1Leukemia, Promyelocytic, Acute 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia 1Kidney Neoplasms 1

Interventions

montanide ISA 51 3Temozolomide 3Ipilimumab 3Interleukin-2 3sargramostim 2incomplete Freund's adjuvant 2glembatumumab vedotin 2aldesleukin 2Vorinostat 2Sunitinib 2Paclitaxel 2MART-1 Antigen 2Lenalidomide 2Dacarbazine 2Cyclophosphamide 2Carboplatin 2CR011-vcMMAE 2Amplified Fragment Length Polymorphism Analysis 2trametinib 1poly ICLC 1omipalisib 1fludarabine phosphate 1fludarabine 1flt3 ligand protein 1entinostat 1cixutumumab 1cediranib 1cabozantinib 1aflibercept 1Taxes 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Uveal Melanoma × flt3 ligand protein × Clear all
NCT02129075 2021-11-16

A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma

National Cancer Institute (NCI)

Phase 2 Completed
60 enrolled 13 charts
Dermatologic

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡